Because human SerpinA3 can also inhibit Cathepsin G (67), whether SerpinA3 can inhibit chronic adipose inflammation to ameliorate obesity and metabolic disorders by targeting Cathepsin G in humans merits further investigation. Here, CTSG is linked to metabolic disease.